Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110

NCT00631878 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Neonatal Staphylococcal Sepsis

Interventions

DRUG: Pagibaximab (formerly BSYX-A110)

Sponsor

Biosynexus Incorporated

Collaborators

[object Object]